Back

An in vivo CRISPR base editing therapy to inactivate the ANGPTL3 gene: nomination of a development candidate for VERVE-201

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: RNA and gene therapy of vascular diseases Gene Therapy, Cell Therapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Amit Khera

Verve Therapeutics, Boston (United States of America)

5 More presentations in this session

Presentation thumbnail
Targeting RNA elongation in endothelial-to-mesenchymal transition
Mr J. Hoba (Leipzig, DE)
Abstract Slides
Presentation thumbnail
Overexpression of miR-210 ameliorates endothelial dysfunction in type 2 diabetic mice
Doctor A. Collado (Stockholm, SE)
Abstract Slides
Presentation thumbnail
Dicer prevents activation of the type I interferon pathway in lipid-loaded macrophages
Mr N. Li (Munich, DE)
Abstract Slides
Presentation thumbnail
Diagnostic ability of miR-19a and Let-7f along with platelet and leukocyte extracellular vesicles in acute ischemic stroke patients
Mrs C. Eyileten (Warsaw, PL)
Abstract Slides
Presentation thumbnail
Targeted overexpression of regnase-1 in the aorta prevents aneurysm growth in a murine model of Marfan syndrome
Miss M. Noormalal (Kiel, DE)
Abstract Slides

Access the full session

Session thumbnail
RNA and gene therapy of vascular diseases

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources